Details for New Drug Application (NDA): 017566
✉ Email this page to a colleague
NDA 017566 describes BREVICON 21-DAY, which is a drug marketed by Allergan and is included in one NDA. Additional details are available on the BREVICON 21-DAY profile page.
The generic ingredient in BREVICON 21-DAY is ethinyl estradiol; norethindrone. There are twenty-six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone profile page.
The generic ingredient in BREVICON 21-DAY is ethinyl estradiol; norethindrone. There are twenty-six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone profile page.
Summary for 017566
| Tradename: | BREVICON 21-DAY |
| Applicant: | Allergan |
| Ingredient: | ethinyl estradiol; norethindrone |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL-21 | Strength | 0.035MG;0.5MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
